IPR v. Ex Parte Reexam Strategy Considerations
February 7, 2024, 7:16 AM
Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!
I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:
- The procedural differences between IPR and Ex Parte Reexamination and associated statistics
- The circumstances when one may be preferable over the other
- The effects of timing and estoppel in parallel litigations
My colleague, Jason Murata, another partner in Axinn’s Intellectual Property group, will be covering, “Recent Developments in the Generic Pharma Industry in the U.S.”

To subscribe to our publications, click here.
News & Insights
News & Insights
CCWC 22nd Annual Career Strategies Conference
Sponsorship
Fordham Competition Law Institute's 53rd Annual Conference on International Antitrust Law and Policy, and Antitrust Economics Workshop
Sponsorship
Antitrust
Women, Influence, & Power in Law Conference 2026
Sponsorship
Antitrust
IP Litigation North America Summit 2026
Sponsorship
Intellectual Property
HNBA/VIA Annual Convention 2026
Sponsorship
Antitrust
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
ABA 2026 Antitrust Global Seminar Series
Speaking Engagement
Antitrust
Axinn Attorneys Earn Top Honors in Best Lawyers 2027
News
Antitrust
DOJ's Antitrust Division Remains Interested in Your Private Litigation
Byline Articles
Antitrust
Axinn Advises Thermo Fisher Scientific on Completed $1.075 Billion Sale of Microbiology Business to Astorg
Deals & Cases
Antitrust